bioRxivGeneticsPreprint
Genetic meta-analysis identifies 9 novel loci and functional pathways for Alzheimers disease risk
Iris E. JanseniD, Jeanne E. SavageiD, Kyoko WatanabeiD, Julien BryoisiD, Dylan M. WilliamsiD, Stacy SteinbergiD, Julia SealockiD, Ida KarlssoniD, Sara HäggiD, Lavinia AthanasiuiD, Nicola Voyle, Petroula ProitsiiD, Aree WitoelariD, Sven StringeriD, Dag AarslandiD, Ina S. AlmdahliD, Fred Andersen, Sverre BerghiD, Francesco BettellaiD, Sigurbjörn Björnsson, Anne Brækhus, Geir BråtheniD, Christiaan de LeeuwiD, Rahul S. DesikaniD, Srdjan DjuroviciD, , Daniëlle PosthumaiD
Abstract
Late onset Alzheimers disease (AD) is the most common form of dementia with more than 35 million people affected worldwide, and no curative treatment available. AD is highly heritable and recent genome-wide meta-analyses have identified over 20 genomic loci associated with AD, yet only explaining a small proportion of the genetic variance indicating that undiscovered loci exist. Here, we performed the largest genome-wide association study of clinically diagnosed AD and AD-by-proxy (71,880 AD cases, 383,378 controls). AD-by-proxy status is based on parental AD diagnosis, and showed strong genetic correlation with AD (rg=0.81). Genetic meta analysis identified 29 risk loci, of which 9 are novel, and implicating 215 potential causative genes. Independent replication further supports these novel loci in AD. Associated genes are strongly expressed in immune-related tissues and cell types (spleen, liver and microglia). Furthermore, gene-set analyses indicate the genetic contribution of biological mechanisms involved in lipid-related processes and degradation of amyloid precursor proteins. We show strong genetic correlations with multiple health-related outcomes, and Mendelian randomisation results suggest a protective effect of cognitive ability on AD risk. These results are a step forward in identifying more of the genetic factors that contribute to AD risk and add novel insights into the neurobiology of AD to guide new drug development.
- organism: human
- assay: GWAS summary statistics
- research focus: GWAS / association mapping
- approach: statistical model
- Citations
- 30
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Meta-analysis of genetic association with diagnosed Alzheimer’s disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing
B K Kunkle, Benjamin Grenier‐Boley, … Clive Holmes·bioRxiv·Apr 5, 2018
- Genome-wide meta-analysis, fine-mapping, and integrative prioritization identify new Alzheimer's disease risk genes
Jeremy Schwartzentruber, Sarah Cooper, … Andrew Roger Bassett·Nature GeneticsPeer-reviewed·Feb 15, 2021
- Identification of 16 novel Alzheimer's disease susceptibility loci using multi-ancestry meta-analyses of clinical Alzheimer's disease and AD-by-proxy cases from four whole genome sequencing datasets
Julian Willett, Mohammad Waqas, … Dmitry Prokopenko·medRxiv·Sep 11, 2024
- Genomic analyses reveal new insights into Alzheimer's disease
Emil Uffelmann, Douglas P. Wightman, … Niccoló Tesi·medRxiv·Oct 10, 2025
- Genome wide association study meta-analysis of neuropathologic lesions of Alzheimer's disease and related dementias in a multi-site autopsy cohort
Brenna Cholerton, Dana Godrich, … Thomas Jude Montine·PLoS GeneticsPeer-reviewed·Jun 29, 2026
- GWAS on family history of Alzheimer’s disease
Riccardo Emilio Marioni, Sarah E. Harris, … Peter M. Visscher·Translational PsychiatryPeer-reviewed·May 18, 2018